Neuromuscular ultrasound as a biomarker in the SOD1 mouse model of amyotrophic lateral sclerosis
PLOS One · 2026
DOI: 10.1371/journal.pone.0353397 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Camilla Wohnrade und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Clinical Neurophysiology, Hannover Medical School, Hannover, Lower Saxony, Germany. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Superoxide Dismutase. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Gesellschaft für Muskelkranke.
Abstract (Originalsprache)
A progression marker that indicates early disease-related changes and treatment responses in the to date incurable neurodegenerative disease amyotrophic lateral sclerosis (ALS) is highly desirable. Translation of therapeutics that have been successful in in vivo models into trials in human patients has proven difficult in recent decades. This failure can be attributed, at least in part, to the lack of specific biomarkers for ALS diagnosis and progression in human ALS patients as well as in in vivo models. Neuromuscular ultrasound is an easily accessible, non-invasive tool to support diagnosis of ALS in humans. Our current study shows for the first time that the disease can be detected in an ALS mouse model with the help of neuromuscular ultrasound. We characterized disease progression regarding changes in the peripheral nerves and muscles of the hind limb in the SOD1 G93A mouse model of ALS using different techniques (neuromuscular ultrasound, electroneurography, motor function tests, phenotypic assessments and histology). By neuromuscular ultrasound, we measured the cross-sectional area and diameter of the sciatic nerve and analyzed hind limb muscle texture and thickness. Our results show that motor neuron loss and muscle atrophy – analogous to ALS in humans – can be measured by ultrasound in the SOD1 G93A mouse model. Changes in nerve and muscle morphology appear at the same time or even before changes in the established tests (including electroneurographic measurements) performed in vivo in this model. Correlations with histologic features of disease progression make neuromuscular ultrasound a sensitive, non-invasive outcome marker for preclinical studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology and Clinical Neurophysiology, Hannover Medical School, Hannover, Lower Saxony, Germany.
- Institute of Neuroanatomy and Cell Biology, Hannover Medical School, Hannover, Lower Saxony, Germany.
- Department of Neurology, Otto-von-Guericke-University Magdeburg, Magdeburg, Saxony-Anhalt, Germany.
- Center for Systems Neuroscience (ZSN) Hannover, Hannover, Lower Saxony, Germany.
ORCID-Profile: Camilla Wohnrade, Kirsten Haastert-Talini
Förderung
- Deutsche Gesellschaft für Muskelkranke
Zitieren
APA
Wohnrade, C., Thau-Habermann, N., Gschwendtberger, T., Rückoldt, J., Huang, Z., Schreiber, S., Haastert-Talini, K., & Petri, S. (2026). Neuromuscular ultrasound as a biomarker in the SOD1 mouse model of amyotrophic lateral sclerosis. PLOS One. https://doi.org/10.1371/journal.pone.0353397
Vancouver
Wohnrade C, Thau-Habermann N, Gschwendtberger T, Rückoldt J, Huang Z, Schreiber S, et al. Neuromuscular ultrasound as a biomarker in the SOD1 mouse model of amyotrophic lateral sclerosis. PLOS One. 2026. doi:10.1371/journal.pone.0353397
BibTeX
@article{Wohnrade2026,
author = {Wohnrade, Camilla and Thau-Habermann, Nadine and Gschwendtberger, Thomas and Rückoldt, Julia and Huang, Zhong and Schreiber, Stefanie and Haastert-Talini, Kirsten and Petri, Susanne},
title = {Neuromuscular ultrasound as a biomarker in the SOD1 mouse model of amyotrophic lateral sclerosis},
journal = {PLOS One},
year = {2026},
doi = {10.1371/journal.pone.0353397}
}
EUVIMED